Maja Ludvigsen

List of Publications by Year
in descending order

54 papers	606 citations	759233 12 h-index	677142 22 g-index
56 all docs	56 docs citations	56 times ranked	1131 citing authors

#	ARTICLE	IF	CITATIONS
1	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia, 2017, 31, 83-91.	7.2	87
2	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood, 2011, 117, 6638-6649.	1.4	79
3	High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Advances, 2017, 1, 1427-1439.	5.2	37
4	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms postâ€"autologous stem cell transplantation. Blood Advances, 2020, 4, 885-892.	5.2	33
5	Melanoma tumors frequently acquire LRP 2 /megalin expression, which modulates melanoma cell proliferation and survival rates. Pigment Cell and Melanoma Research, 2015, 28, 267-280.	3.3	30
6	A systematic review of biomarkers in the diagnosis of infective endocarditis. International Journal of Cardiology, 2016, 202, 564-570.	1.7	27
7	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer Journal, 2017, 7, 654.	6.2	26
8	Proteomic Characterization of Colorectal Cancer Cells versus Normal-Derived Colon Mucosa Cells: Approaching Identification of Novel Diagnostic Protein Biomarkers in Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 3466.	4.1	26
9	Identification and characterization of novel ERCâ€55 interacting proteins: Evidence for the existence of several ERCâ€55 splicing variants; including the cytosolic ERCâ€55â€C. Proteomics, 2009, 9, 5267-5287.	2.2	16
10	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica, 2020, 105, 2432-2439.	3.5	16
11	Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. Cancers, 2021, 13, 398.	3.7	16
12	Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation. OncoTargets and Therapy, 2017, Volume 10, 1977-1982.	2.0	13
13	High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma. Blood Cancer Journal, 2019, 9, 35.	6.2	11
14	Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. Leukemia and Lymphoma, 2020, 61, 2584-2594.	1.3	11
15	Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma. Blood Cancer Journal, 2015, 5, e293-e293.	6.2	10
16	Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. Blood Advances, 2018, 2, 1562-1571.	5.2	10
17	Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machineâ€learning assisted morphometrics. Cytometry Part B - Clinical Cytometry, 2021, 100, 554-567.	1.5	10
18	Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis. International Journal of Infectious Diseases, 2020, 96, 73-81.	3.3	10

#	Article	IF	Citations
19	Proteomic approaches to the study of malignant lymphoma: Analyses on patient samples. Proteomics - Clinical Applications, 2015, 9, 72-85.	1.6	9
20	PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation. OncoTargets and Therapy, 2021, Volume 14, 481-489.	2.0	9
21	Glycolytic biomarkers predict transformation in patients with follicular lymphoma. PLoS ONE, 2020, 15, e0233449.	2.5	9
22	Relationship of intratumoural protein expression patterns to age and <scp>E</scp>pstein–<scp>B</scp>arr virus status in classical <scp>H</scp>odgkin lymphoma. European Journal of Haematology, 2015, 95, 137-149.	2.2	8
23	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. Blood Advances, 2018, 2, 2533-2542.	5.2	8
24	Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2502-2506.	3.5	8
25	Serum Proteomic Changes after Randomized Prolonged Erythropoietin Treatment and/or Endurance Training: Detection of Novel Biomarkers. PLoS ONE, 2015, 10, e0117119.	2.5	6
26	Diurnal expression of proteins in the retina of the blind cone–rod homeobox (<i>Crx</i>^{<i>–/–</i>}) mouse and the 129/Sv mouse: a proteomic study. Acta Ophthalmologica, 2017, 95, 717-726.	1.1	6
27	High intratumoural galectin–1 expression predicts adverse outcome in ALK – ALCL and CD30 + PTCL–NOS. Hematological Oncology, 2020, 38, 59-66.	1.7	6
28	Soluble programmed cell death protein 1 (sPD–1) and the soluble programmed cell death ligands 1 and 2 (sPD–L1 and sPD–L2) in lymphoid malignancies. European Journal of Haematology, 2021, 107, 81-91.	2.2	6
29	Proteomic Analysis of Tissue from Î±1,3-galactosyltransferase Knockout Mice Reveals That a Wide Variety of Proteins and Protein Fragments Change Expression Level. PLoS ONE, 2013, 8, e80600.	2.5	6
30	Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity. BMC Biochemistry, 2009, 10, 34.	4.4	5
31	Fibulin-1C, C1 Esterase Inhibitor and Glucose Regulated Protein 75 Interact with the CREC Proteins, Calumenin and Reticulocalbin. PLoS ONE, 2015, 10, e0132283.	2.5	5
32	Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development. Aids, 2016, 30, 1889-1898.	2.2	5
33	IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. Haematologica, 2022, 107, 877-886.	3.5	5
34	Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation. Case Reports in Hematology, 2021, 2021, 1-5.	0.4	4
35	Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 460-465.	2.4	4
36	Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients. Cancers, 2022, 14, 1316.	3.7	4

#	Article	IF	Citations
37	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia. Cancers, 2021, 13, 5526.	3.7	3
38	Differential protein expression of peroxiredoxin‐1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. Hematological Oncology, 2015, 33, 253-255.	1.7	2
39	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. Aids, 2017, 31, 2311-2313.	2.2	2
40	Unraveling clonal heterogeneity at the stem cell level in myelodysplastic syndrome: In pursuit of cell subsets driving disease progression. Leukemia Research, 2020, 92, 106350.	0.8	2
41	Proteomic Characterization of Colorectal Cancer Tissue from Patients Identifies Novel Putative Protein Biomarkers. Current Issues in Molecular Biology, 2021, 43, 1043-1056.	2.4	2
42	Intratumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. Acta Oncológica, 2021, 60, 1637-1642.	1.8	2
43	Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling. Cancers, 2022, 14, 247.	3.7	2
44	Immunophenotypically defined stem cell subsets in paediatric <scp>AML</scp> are highly heterogeneous and demonstrate differences in <scp>BCL</scp>‐2 expression by cytogenetic subgroups. British Journal of Haematology, 2022, 197, 452-466.	2.5	2
45	Perturbations of urea cycle enzymes during posthepatectomy rat liver failure. American Journal of Physiology - Renal Physiology, 2019, 317, G429-G440.	3.4	1
46	Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma. Blood, 2019, 134, 2776-2776.	1.4	1
47	Imaging flow cytometry reveals a subset of TdT negative T‐ALL blasts with very low forward scatter on conventional flow cytometry. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	1
48	Clonal Hematopoiesis Drives Therapy-Related Myeloid Neoplasms Following Autologous Stem Cell Transplantation and Propagates during Disease Evolution. Blood, 2020, 136, 15-16.	1.4	1
49	Upfront Rituximab Maintenance after Induction Therapy Improves Outcome and Reduces the Risk of Histological Transformation in Patients with Follicular Lymphoma - Real World Data from a Danish Population-Based Cohort. Blood, 2016, 128, 1783-1783.	1.4	0
50	Low Serum Galectin-1 Levels Predict Future Lymphoma Development in HIV-Positive Patients. Blood, 2016, 128, 2945-2945.	1.4	0
51	High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL. Blood, 2016, 128, 4142-4142.	1.4	0
52	Therapy-Related Myeloid Neoplasms Following Autologous Stem Cell Transplantation: The Prevalence of Chip Mutations at Time of Transplantation â€" a Single Center Experience. Blood, 2018, 132, 1529-1529.	1.4	0
53	CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia and Lymphoma, 2022, , 1-5.	1.3	0
54	Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia. Danish Medical Journal, 2017, 64, .	0.5	0